COMP <GO>
JAZZ vs LLY // REVENUE GROWTH (YOY)
Jazz Pharmaceuticals plc Common Stock (Ireland) (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: JAZZ 2
— LLY 12
▲ REVENUE GROWTH (YOY) LEADER: LLY
LAST: $215.98 (+3.92%) • MKT CAP: $13.49B
revenue-growth
4.90%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
revenue-growth
45.51%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (JAZZ VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | JAZZ | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 83.64% | -42.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -4.70% | 32.36% | -37.06 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 9.61% | 2.30% | +7.31 | JAZZ | /fcf-yield <GO> |
| Operating Margin | -10.10% | 40.21% | -50.31 | LLY | /operating-margins <GO> |
| Net Profit Margin | -8.30% | 31.90% | -40.20 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 4.90% | 45.51% | -40.61 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.97 | 9.29 | -7.32 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.77% | +0.43 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.4 | 77.9 | -31.50 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.09 | 0.51 | +0.58 | JAZZ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 36.0x | 26.3x | +9.75 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $13.49B | $1.33T | -$1.32T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | JAZZ REV | LLY REV | JAZZ GROSS % | LLY GROSS % | JAZZ FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.27B | $65.18B | 44.0% | 83.0% | $1.30B | $16.81B |
| FY 2024 | $4.07B | $45.04B | 44.0% | 81.3% | $1.36B | $8.82B |
| FY 2023 | $3.83B | $34.12B | 44.0% | 79.3% | $919.5M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
JAZZ // BETA 1.09
LLY // BETA 0.51